Ibio Common Stock Stock Performance
| IBIO Stock | USD 2.25 0.14 5.86% |
IBio Common holds a performance score of 9 on a scale of zero to a hundred. The firm retains a Market Volatility (i.e., Beta) of 0.23, which attests to not very significant fluctuations relative to the market. As returns on the market increase, IBio Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding IBio Common is expected to be smaller as well. Use iBio Common Stock downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on iBio Common Stock.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in iBio Common Stock are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady forward indicators, IBio Common displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.86) | Year To Date Return 11.39 | Ten Year Return (99.92) | All Time Return (99.95) |
Last Split Factor 1:20 | Dividend Date 2018-06-11 | Last Split Date 2023-11-29 |
1 | Financial Comparison iBio and Its Peers | 11/10/2025 |
2 | Comparing iBio and Its Competitors | 11/13/2025 |
3 | Insider Trading | 11/14/2025 |
4 | 19,654,625 Common Stock of iBio, Inc. are subject to a Lock-Up Agreement Ending on 18-NOV-2025. - MarketScreener | 11/17/2025 |
5 | Acquisition by Arkowitz David of 13500 shares of IBio, Common at 1.0 subject to Rule 16b-3 | 11/20/2025 |
6 | Acquisition by Schimmelpennink Evert B. of 13500 shares of IBio, Common at 1.0 subject to Rule 16b-3 | 11/28/2025 |
7 | iBio Stock Jumps on Obesity Drug Momentum All the Latest News, Analyst Targets and 20262027 Outlook - ts2.tech | 12/09/2025 |
8 | What is Lifesci Capitals Estimate for iBio Q2 Earnings | 12/24/2025 |
9 | 12 Health Care Stocks Moving In Fridays Pre-Market Session | 01/09/2026 |
| Begin Period Cash Flow | 14.4 M | |
| Total Cashflows From Investing Activities | 742 K |
IBio Common Relative Risk vs. Return Landscape
If you would invest 139.00 in iBio Common Stock on October 28, 2025 and sell it today you would earn a total of 86.00 from holding iBio Common Stock or generate 61.87% return on investment over 90 days. iBio Common Stock is currently generating 1.3011% in daily expected returns and assumes 10.6014% risk (volatility on return distribution) over the 90 days horizon. In different words, 95% of stocks are less volatile than IBio, and 74% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IBio Common Target Price Odds to finish over Current Price
The tendency of IBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.25 | 90 days | 2.25 | about 13.19 |
Based on a normal probability distribution, the odds of IBio Common to move above the current price in 90 days from now is about 13.19 (This iBio Common Stock probability density function shows the probability of IBio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days IBio Common has a beta of 0.23. This usually indicates as returns on the market go up, IBio Common average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding iBio Common Stock will be expected to be much smaller as well. Moreover IBio Common Stock has an alpha of 1.9493, implying that it can generate a 1.95 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). IBio Common Price Density |
| Price |
Predictive Modules for IBio Common
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as iBio Common Stock. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.IBio Common Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. IBio Common is not an exception. The market had few large corrections towards the IBio Common's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold iBio Common Stock, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of IBio Common within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.95 | |
β | Beta against Dow Jones | 0.23 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | 0.17 |
IBio Common Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of IBio Common for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for iBio Common Stock can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| iBio Common Stock is way too risky over 90 days horizon | |
| iBio Common Stock appears to be risky and price may revert if volatility continues | |
| iBio Common Stock has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 400 K. Net Loss for the year was (18.38 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| iBio Common Stock currently holds about 33.52 M in cash with (15.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: 12 Health Care Stocks Moving In Fridays Pre-Market Session |
IBio Common Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of IBio Stock often depends not only on the future outlook of the current and potential IBio Common's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. IBio Common's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.5 M | |
| Cash And Short Term Investments | 8.6 M |
IBio Common Fundamentals Growth
IBio Stock prices reflect investors' perceptions of the future prospects and financial health of IBio Common, and IBio Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IBio Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (59.51) % | ||||
| Current Valuation | 4.31 M | ||||
| Shares Outstanding | 22.49 M | ||||
| Price To Earning | (2.18) X | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 101.19 X | ||||
| Revenue | 400 K | ||||
| Gross Profit | 500 K | ||||
| EBITDA | (17.04 M) | ||||
| Net Income | (18.38 M) | ||||
| Cash And Equivalents | 33.52 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 3.51 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 1.48 X | ||||
| Book Value Per Share | 2.77 X | ||||
| Cash Flow From Operations | (15.3 M) | ||||
| Earnings Per Share | (1.40) X | ||||
| Market Capitalization | 50.6 M | ||||
| Total Asset | 23.18 M | ||||
| Retained Earnings | (332.22 M) | ||||
| Working Capital | 3.62 M | ||||
| Current Asset | 23.91 M | ||||
| Current Liabilities | 2.29 M | ||||
About IBio Common Performance
By examining IBio Common's fundamental ratios, stakeholders can obtain critical insights into IBio Common's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that IBio Common is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 431.82 | 422.46 | |
| Return On Tangible Assets | (1.01) | (1.06) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.11) | (1.17) |
Things to note about iBio Common Stock performance evaluation
Checking the ongoing alerts about IBio Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for iBio Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| iBio Common Stock is way too risky over 90 days horizon | |
| iBio Common Stock appears to be risky and price may revert if volatility continues | |
| iBio Common Stock has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 400 K. Net Loss for the year was (18.38 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| iBio Common Stock currently holds about 33.52 M in cash with (15.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: 12 Health Care Stocks Moving In Fridays Pre-Market Session |
- Analyzing IBio Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IBio Common's stock is overvalued or undervalued compared to its peers.
- Examining IBio Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IBio Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of IBio Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IBio Common's stock. These opinions can provide insight into IBio Common's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio Common. If investors know IBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share | Quarterly Revenue Growth 0.143 | Return On Assets | Return On Equity |
The market value of iBio Common Stock is measured differently than its book value, which is the value of IBio that is recorded on the company's balance sheet. Investors also form their own opinion of IBio Common's value that differs from its market value or its book value, called intrinsic value, which is IBio Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio Common's market value can be influenced by many factors that don't directly affect IBio Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.